Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1443421-70-2Abacavir N-Oxide Impurity

● Under Development

Catalogue No.:	VL760010
CAS No.:	1443421-70-2
Mol. Formula:	C14H18N6O2
Mol. Weight:	302.34 g/mol

How can we help?

Add to RFQ list

Additional information on CAS 1443421-70-2

Parent drug

Abacavir

IUPAC Name

(1S,4R )-[4-[2-Amino-6-( cyclopropyl amino)-7-oxo-9H-purine-9-yl]cyclopent-2-en-1-yl]methanol

Pharmacopoeial Synonyms

N/A

Other Synonyms

(1S,4R)-4-(2-Amino-6-(cyclopropylamino)-7-oxido-9H-purin-9-yl)-2-cyclopentene-1-methanol; 2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-7-oxido-9H-purin-9-yl)-, (1S,4R)-

Description

Abacavir N-Oxide Impurity (CAS 1443421-70-2) is an oxidative metabolite-related process impurity of the carbocyclic nucleoside reverse transcriptase inhibitor abacavir, formed by oxygen insertion at the ring nitrogen to give an N-oxide functionality. With molecular formula C14H18N6O2 and molecular weight 302.34 g/mol, it is a polar, heteroaromatic species expected to exhibit distinct chromatographic behavior from the parent drug. Its determination commonly requires LC-MS/MS or LC-HRMS, with UV detection often insufficient for unequivocal assignment. In impurity profiling, it is evaluated as a structurally related degradant or synthesis-related variant under impurity control strategies consistent with ICH principles.

References

Foster RH, Faulds D. Abacavir. Drugs. 1998 May;55(5):729-36; discussion 737-8. DOI: 10.2165/00003495-199855050-00018. PMID: 9585869. ?Vukkum, Pallavi. “Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, Its Related Substances, and Degradation Products.” Scientia Pharmaceutica, vol. 80, no. 4, 2012, pp. 903–21, https://doi.org/10.3797/scipharm.1206-11.